Dynavax commences Phase 1 trial in lupus program
The execution of the trial entitles Dynavax to receive a $6m milestone payment from GSK, its partner in a worldwide strategic alliance. As per the terms of the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.